 |
|
|
| |
Implementation of Cabotegravir and Rilpivirine Long-Acting (CAB + RPV LA): Primary
Results From the CAB + RPV Implementation Study in European Locations (CARISEL)
|
| |
| |
HIV Drug Therapy Glasgow; October 23-26, 2022; Virtual and Glasgow, Scotland
Berend J. van Welzen1, Linos Vandekerckhove2, Celia Jonsson-Oldenbüttel3, Laurent Hocqueloux4, Mounir Ait-Khaled5, Gilda Bontempo6, Rebecca DeMoor7, Jenny Scherzer8, Ronald D'Amico6, Nicola Barnes9, Monica Hadi9, Emma L. Low9, Savita Bakhshi Anand9, Maggie Czarnogorski6, Cassidy A. Gutner6
1UMC Utrecht, Utrecht, The Netherlands; 2University Hospital Ghent, Ghent, Belgium; 3MVZ München am Goetheplatz, MUC Research GmbH, Munich, Germany; 4CHR d'Orléans, Hôpital de la Source, Orléans, France;
5ViiV Healthcare, Brentford, United Kingdom; 6ViiV Healthcare, Research Triangle Park, NC, United States; 7GSK, Collegeville, PA, United States; 8ViiV Healthcare GmbH, Munich, Germany; 9Evidera, London, United Kingdom
|
| |
|
|
|
|
|
